Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies..

赛诺菲与私人临床阶段生物制药公司Dren Bio, Inc.达成了一项最终协议，根据该协议，赛诺菲同意收购DR-0201，这是一种靶向双特异性髓系细胞接合器（MCE），在临床前和早期临床研究中显示出强大的B细胞清除效果。

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent early clinical study data in autoimmune diseases suggest that deep B-cell depletion might have the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain..

DR-0201 是一种潜在的首创 CD20 导向的双特异性抗体，可靶向并结合特定的组织驻留和迁移性髓系细胞，通过靶向吞噬作用诱导深度 B 细胞耗竭。近期在自身免疫疾病中的早期临床研究数据显示，深度 B 细胞耗竭可能具有重置适应性免疫系统的潜力，从而为难治性 B 细胞介导的自身免疫疾病（如狼疮）患者带来持续的无治疗缓解，而这些疾病仍存在显著未满足的医疗需求。

Houman Ashrafian

侯曼·阿什拉菲安

Head of Research and Development, Sanofi

研发负责人，赛诺菲公司

“Deep B-cell depletion is at the frontier of treating autoimmune diseases and using the myeloid cell engager DR-0201 has the potential to elevate the treatment effect for patients, in particular patients refractory to existing treatments. This is yet another important step in Sanofi’s ambition to bring breakthrough medicines to patients, and further strengthens our robust pipeline focused on the immune system.

“深度B细胞耗竭是治疗自身免疫性疾病的前沿，而使用髓系细胞结合剂DR-0201有潜力提升患者的治疗效果，尤其是对现有治疗产生耐药性的患者。这是赛诺菲致力于为患者带来突破性药物的又一重要步骤，同时也进一步巩固了我们专注于免疫系统的强大研发管线。”

Through our own research and strategic licensing and acquisitions, we continue to advance our goal of becoming the leader in immunology.”.

通过我们自己的研究以及战略性许可和收购，我们不断推进成为免疫学领域领导者的这一目标。”

Nenad Tomasevic

内纳德·托马舍维奇

Co-founder and CEO, Dren Bio

Dren Bio联合创始人兼首席执行官

“Dren Bio is committed to redefining treatment possibilities in immunology, oncology, and other therapeutic areas with our targeted myeloid engager and phagocytosis platform. It has been a privilege to advance our lead platform program, DR-0201 into clinical development and evaluate its potential to achieve potent B-cell depletion.

“Dren Bio致力于通过我们靶向髓系细胞的连接器和吞噬作用平台，重新定义免疫学、肿瘤学及其他治疗领域的可能性。能够将我们的领先平台项目DR-0201推进到临床开发阶段，并评估其在实现有效B细胞清除方面的潜力，是一种荣幸。

As a leader in immunology, Sanofi is ideally positioned to unlock the power of deep B-cell depletion and immune reset for autoimmune patients with this novel myeloid cell engager.”.

“作为免疫学领域的领导者，赛诺菲处于理想位置，能够通过这种新型髓系细胞接合器释放深度B细胞耗竭和免疫重置对自身免疫病患者的力量。”

About DR-0201

关于 DR-0201

DR-0201 is the first bispecific antibody from Dren Bio’s targeted myeloid engager and phagocytosis platform, which acts by engaging tissue-resident and trafficking myeloid cells to induce deep B-cell depletion. DR-0201 is being evaluated in two ongoing phase 1 studies and has shown deep and robust B-cell depletion in non-clinical and clinical settings..

DR-0201是Dren Bio公司靶向髓系细胞结合和吞噬平台中的首个双特异性抗体，它通过吸引组织驻留和迁移的髓系细胞来诱导深度B细胞清除。DR-0201正在两项进行中的1期临床研究中接受评估，并在非临床和临床环境中显示出深度且强劲的B细胞清除效果。

Financial Considerations

财务考量

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totaling $1.3 billion upon achievement of certain development and launch milestones.

根据合并协议的条款，赛诺菲将通过收购Dren Bio的子公司Dren-0201来获得DR-0201，预付款为6亿美元，并在达成某些开发和上市里程碑后，可能追加支付总计13亿美元的未来款项。

After the acquisition of Dren-0201, Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.

在收购Dren-0201后，Dren Bio将继续独立运营，推进其选择性清除致病细胞和其他致病因子的抗体治疗产品管线。

Sanofi’s acquisition of Dren-0201 is subject to closing conditions, including receipt of regulatory approvals. The companies expect the transaction to close during Q2 2025.

赛诺菲对Dren-0201的收购取决于成交条件，包括获得监管机构的批准。两家公司预计该交易将于2025年第二季度完成。

Sanofi expects to finance the transaction with available cash resources.

赛诺菲预计将以现有的现金资源为这笔交易融资。

About Dren Bio

关于Dren Bio

Dren Bio is a privately held, clinical-stage biopharmaceutical company pioneering the discovery and development of novel first-in-class antibody therapeutics for the treatment of cancer, autoimmune, and other serious diseases. Dren Bio’s lead product candidate, DR-01, is currently being evaluated in oncology and autoimmune indications.

Dren Bio是一家私人控股的临床阶段生物制药公司，致力于为癌症、自身免疫疾病及其他严重疾病的治疗发现和开发新型首创新抗体疗法。Dren Bio的主要候选产品DR-01目前正在肿瘤和自身免疫适应症中进行评估。

In addition, Dren Bio’s targeted myeloid engager and phagocytosis platform is a bispecific antibody-based technology that induces potent depletion of disease-causing agents by engaging a novel phagocytic receptor that is selectively expressed on myeloid cells and activated only in the presence of the target antigen.

此外，Dren Bio的靶向髓系接合剂和吞噬作用平台是一种基于双特异性抗体的技术，通过结合一种新型的吞噬受体，该受体选择性表达于髓系细胞上，并仅在目标抗原存在时激活，从而有效清除致病因子。

For more information about Dren Bio and its current development pipeline, please visit Dren Bio’s website at .

有关Dren Bio及其当前开发管线的更多信息，请访问Dren Bio的网站。

About Sanofi

关于赛诺菲

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions..

我们是一家创新的全球医疗保健公司，由一个目标驱动：我们追逐科学的奇迹以改善人们的生活。我们的团队遍布全球，致力于通过努力将不可能变为可能来改变医学实践。我们为全球数百万人提供可能改变生命的治疗选择和拯救生命的疫苗保护，同时将可持续发展和社会责任置于我们追求的核心。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在EURONEXT上市，代码为SAN，在NASDAQ上市，代码为SNY。